Le Lézard
Classified in: Health, Science and technology
Subject: DIS

MyndTec and University Health Network Extend Partnership focusing on advances in technology to improve lives of people living with the effects of disability


MISSISSAUGA, ON, July 14, 2020 /CNW/ - MyndTec Inc., an award-winning Canadian medical technology company, and University of Health Network (UHN), Canada's largest medical research hospital, have announced the extension of an exclusive license agreement.  The partnership positions MyndTec at the forefront of new technology in the neuromodulation and neurorehabilitation field.

The partnership, established in 2012, has culminated in the development and commercialization of MyndMovetm Therapy in the U.S. and Canada.  MyndMovetm is a non-invasive functional electrical stimulation technology that assists those living with paralysis following stroke or spinal cord injury by helping restore arm and hand function.   The collaboration reflects the company's commitment to addressing an important need in neurorehabilitation.   

"This partnership allows our research teams to rapidly develop and commercialize new products designed to restore function for people living with disabilities," said Steven Plymale, CEO of MyndTec.   The research and development of MyndMovetm was pioneered by Dr. Milos R. Popovic and the research team at KITE, the research arm of the Toronto Rehabilitation Institute and one of UHN's principle research enterprises.  "We are thrilled to extend the agreement and look forward to working with MyndTec to bring to market high-tech innovations developed in our labs," said Dr. Popovic, KITE Institute Director.

About MyndTec

MyndTec Inc. is a privately held medical technology company located in Mississauga, Ontario, that commercializes innovative therapeutic medical devices designed to improve function, maximize independence, and enhance quality of life.  MyndTec's product MyndMovetm is a non-invasive functional electrical stimulation-based intervention. MyndMovetm uses the phenomenon of neuroplasticity to stimulate development of new neural pathways to assist those with paralysis following a stroke or spinal cord injury to regain control of their arms and hands. 

For more information on MyndMovetm and authorized indications visit http://www.myndtec.com.

The Kite Research Institute

KITE is the research arm of the Toronto Rehabilitation Institute and one of the principle research enterprises at the University Health Network, Canada's largest medical research hospital.  KITE is a world leader in the field of the complex rehabilitation research, with scientists and staff dedicated to improving the lives of people living with the effects of disability, illness and aging.

SOURCE MyndTec Inc.


These press releases may also interest you

at 07:05
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you...

at 07:05
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...

at 07:05
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...

at 07:05
Enterprises in France, seeking better returns on investment, are turning to service providers that can manage their Salesforce platforms more efficiently, according to a new research report published today by Information Services Group (ISG) , a...

at 07:05
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the...



News published on and distributed by: